Astellas Pharma Inc.

OTC: ALPMY · Real-Time Price · USD
11.33
0.15 (1.34%)
At close: Aug 15, 2025, 3:58 PM
11.30
-0.26%
After-hours: Aug 15, 2025, 03:58 PM EDT

Astellas Pharma Income Statement

Financials in JPY. Fiscal year is April - March.
Fiscal Year Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020
Revenue
459.29B 517.41B 462.5B 473.12B 414.6B 421.93B 392.15B 374.99B 354.25B 402.18B 380.39B 381.79B 303.87B 340.63B 325.52B 326.14B 308.62B 325.43B 308.51B 306.97B
Cost of Revenue
76.86B 98.52B 82.69B 91.14B 105.88B 108.34B 99.08B 78.02B 71.54B 83.63B 72B 99.61B 66.95B 77.23B 68.92B 68.19B 64.8B 68.19B 59.9B 59.65B
Gross Profit
382.44B 418.88B 379.81B 381.99B 308.73B 313.6B 293.07B 296.98B 282.71B 318.55B 308.39B 282.18B 236.92B 263.4B 256.6B 257.95B 243.82B 257.24B 248.62B 247.31B
Operating Income
63.52B -116.19B 63.17B 53.32B 37.72B 39.71B 36.44B 64.2B 53.34B 88.65B 88.66B 54.77B 26.14B 68.9B 62.46B 62.53B 46.88B 72.59B 26.3B 60.84B
Interest Income
n/a n/a n/a 162M 4.12B 1.18B 2.37B 3.78B 2.44B 1.17B 3.56B 927M 3.84B 417M 432M 1.46B 5.1B 3.06B 3.07B 379M
Pretax Income
60.55B -118.36B 38.55B 50.49B -45.96B 17.54B 6.25B 46.16B -47.77B 60.16B 87.37B 31.33B -8.97B 76.59B 53.24B 35.54B -19.65B 75.14B 28.85B 60.24B
Net Income
74.9B -97.66B 35.91B 37.6B -33.28B 14.51B -1.46B 33.13B -46.13B 48.41B 71.62B 24.81B -8.41B 60.88B 40.92B 30.69B -12.33B 60.08B 22.43B 50.41B
Selling & General & Admin
211.32B 225.31B 199.53B 206.88B 193.15B 199.5B 179.28B 168.18B 159.29B 163.02B 154.56B 153.4B 142.42B 135.91B 133.4B 137.11B 141.27B 120.91B 121.36B 120.78B
Research & Development
76.23B 79.09B 85.51B 86.82B 77.85B 74.39B 77.36B 64.59B 70.08B 66.88B 65.17B 74.01B 68.36B 58.59B 60.75B 58.31B 55.67B 57.12B 54.41B 57.29B
Other Expenses
31.37B 230.68B 31.6B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
318.92B 535.08B 316.64B 331.33B 271B 273.89B 256.63B 232.77B 229.37B 229.9B 219.73B 227.4B 210.78B 194.5B 194.14B 195.42B 196.94B 184.64B 222.56B 186.5B
Interest Expense
n/a n/a n/a 324M 4.19B 2.83B 2.27B 2.72B 2.07B 2.8B 1.51B 2.4B 675M 1.3B 1.25B 1.72B 589M 520M 271M 956M
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
395.77B 633.6B 399.33B 422.47B 376.88B 382.22B 355.71B 310.79B 300.91B 313.53B 291.73B 327.02B 277.73B 271.73B 263.06B 263.62B 261.74B 252.83B 282.45B 246.15B
Income Tax Expense
-14.34B -20.7B 2.64B 12.89B -15.38B 2.8B 6.79B 13.72B -1.75B 11.35B 17.18B 6.87B -2.11B 17.43B 12.33B 5.14B -6.58B 15.06B 6.43B 9.82B
Shares Outstanding (Basic)
1.82B 1.79B 1.8B 1.8B 1.79B 1.79B 1.79B 1.79B 1.81B 1.82B 1.82B 1.83B 1.84B 1.85B 1.85B 1.85B 1.86B 1.86B 1.86B 1.86B
Shares Outstanding (Diluted)
1.82B 1.79B 1.8B 1.8B 1.79B 1.8B 1.79B 1.8B 1.81B 1.82B 1.82B 1.83B 1.84B 1.85B 1.85B 1.85B 1.86B 1.86B 1.86B 1.86B
EPS (Basic)
41.83 -54.57 20.06 20.94 -18.56 8.09 -0.81 18.46 -25.49 26.56 39.30 13.60 -4.57 32.86 22.09 16.56 -6.64 32.33 12.07 27.12
EPS (Diluted)
41.19 -54.57 19.97 20.94 -18.56 8.06 -0.81 18.42 -25.49 26.55 39.28 13.59 -4.57 32.84 22.07 16.55 -6.64 32.33 12.07 27.12
EBITDA
101.78B 126.06B 88.05B 103.59B 4.17B 67.13B 46.57B 72.81B -22.79B 85.56B 113.16B 70.95B 11.24B 101.14B 73.45B 55.69B 65.45B 90.74B 44.24B 78.84B
EBIT
54.1B 74.89B 38.03B 54.99B -44.48B 20.14B 7.6B 49.57B -45.8B 62.56B 90.31B 34.08B -9.84B 79.62B 54.51B 37.55B -18.31B 75.66B 29.12B 61.19B
Depreciation & Amortization
47.68B 51.16B 50.02B 50.27B 48.64B 46.98B 38.97B 23.24B 23.02B 23B 22.85B 36.87B 21.08B 21.52B 18.94B 18.14B 18.56B 18.15B 17.94B 18B